Skip to Main Content
Contribute Try STAT+ Today

Livongo, a startup that monitors and coaches patients with chronic diseases, on Friday filed papers to launch its initial public offering, in what is seen as a litmus test for health-tech companies seeking to translate early growth into value in the public markets.

The offering is expected to be among the first for a new generation of slick and savvy venture-backed companies in the U.S. digital health sector, which hasn’t produced an IPO since 2016. (Another such company, medical records data startup Health Catalyst, filed to go public on Thursday.) Livongo’s offering had been anticipated for several months, as the company has been expanding rapidly and running studies to try to show that its services can improve patients’ outcomes and save their employers money. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.